



IPSOGEN
CANCER PROFILER

PRESS RELEASE

IPSOGEN issues favorable opinion on QIAGEN's offer – QIAGEN enters into agreements to acquire 61% stake in IPSOGEN – Qiagen announces launching of a public tender offer to acquire all of the remaining shares of IPSOGEN

Marseilles, France, July 8, 2011 – IPSOGEN S.A. (Alternext: ALIPS, ISIN: FR0010626028) announces today that its Board of Directors met on July 8, 2011 and issued a favorable preliminary opinion on QIAGEN's offer, subject to the review of the offer documents and of the report of the independent expert appointed in connection with the tender offer.

QIAGEN's offer to purchase an initial stake of approximately 47% in IPSOGEN S.A., made on June 15, 2011, has been accepted by its beneficiaries and, as announced, has been implemented at a price of euro 12.90 per share.

IPSOGEN's works council has been consulted and has rendered a favorable opinion on QIAGEN's offer.

QIAGEN has also entered into agreements with certain shareholders of IPSOGEN in order to purchase an additional 14% stake in IPSOGEN S.A., which will trigger the upwards crossing of the 50% threshold.

The settlement-delivery for those purchases is expected to take place on July 12, 2011. The composition of IPSOGEN's Board of Directors will subsequently be modified in order to reflect QIAGEN's stake in IPSOGEN.

As previously announced and pursuant to applicable regulations, QIAGEN will launch a public tender offer for all the remaining outstanding securities composing IPSOGEN's capital, at a price of euro 12.90 per share. Since it follows the crossing of the 50% threshold, such public tender offer will be subject to the AMF's clearance. Should QIAGEN reach the 95% threshold in IPSOGEN's capital or voting rights, QIAGEN will reserve the right to request for the implementation of a squeeze-out procedure at the same price.

"QIAGEN's offer satisfies both the historical shareholders who have been supporting IPSOGEN's development since inception as well as the company's employees, for whom joining QIAGEN's group, a major player in the molecular diagnostics industry, represents an opportunity to maximize not only the valuation of Ipsogen's products and projects but also its recognized and specific know-how. The combination will also benefit IPSOGEN's customers and scientific partners, who are instrumental to personalized treatments of cancers" said Vincent Fert, CEO of IPSOGEN.

Shearman & Sterling LLP is acting as legal advisor to IPSOGEN in relation to this offer. Rothschild and Kempen & Co. are acting as financial advisors and Darrois Villey Maillot Brochier is acting as legal advisor to QIAGEN in relation to this offer.

About IPSOGEN

IPSOGEN, cancer profiler, develops and markets molecular diagnostic tests that help to map diseases and guide patients and oncologists' decisions along their therapeutic path.

With more than 80 tests already used routinely worldwide for the diagnosis, prognosis and follow up of thousands of patients with leukemia, IPSOGEN is now targeting breast cancer with the aim of providing currently inaccessible diagnostic information.

Strengthened by its scientific, clinical and technological partnerships, and by its multidisciplinary team in France and the USA, IPSOGEN intends to become a world leader in the molecular profiling of cancers, and to continue the development and promotion of best-in-class diagnostic references that have a significant impact on patients, medical professionals and society. The company is headquartered in Marseille, France, and has a subsidiary in the USA. For further information, visit www.ipsogen.com.



IPSOGEN
CANCER PROFILER

PRESS RELEASE

About QIAGEN

QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated bio-molecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics. QIAGEN employs nearly 3,600 people in over 30 locations worldwide. Further information about QIAGEN can be found at <http://www.qiagen.com/>.

Contacts

IPSOGEN

Pascale Boissel

CFO

Tel: + 33 (0)4 9129 3090

pascale.boissel@ipsogen.com

Vincent Fert

CEO

Tel: + 33 (0)4 9129 3090

fert@ipsogen.com

NewCap.

Financial communication
& Investor relations

Axelle Vuillermet &

Pierre Laurent

Tel: + 33 (0)1 44 71 94 93

ipsogen@newcap.fr

ALIPS
LISTED
NYSE
ALTERNEXT